![]() Where iOS 11 differs from earlier versions is that the webview content now respects the safe areas. There is another awkward situation with the notch, the safe area, and fixed positioning. ( Update: when the iPhone X first came out, it used constant() instead of env(), but as of 11.2, constant() has been removed in favor of the standardized env()). padding: env(safe-area-inset-top) env(safe-area-inset-right) env(safe-area-inset-bottom) env(safe-area-inset-left) I added the following to the main container on the website. This can be added to margin, padding, or absolute position values such a top or left. In order to handle any adjustment that may be required iOS 11’s version of Safari includes some constants that can be used when viewport-fit=cover is being used. There is some new CSS that helps you accommodate for that. Then it’s on you to account for any overlapping that normally would have been handled by the safe area. Or, expand the website the whole area (notch be damned), you can add viewport-fit=cover to your meta viewport tag. It’s not much of a trick to remove it though, a background-color on the body will do. The result is some awkward situations for screen design, like constraining websites to a “safe area” and having white bars on the edges. This has led to a change in our practice toward offering PBT as the first-line treatment for these patients.īrachytherapy COB plaque Juxtapapillary choroidal melanoma Notched plaque Ruthenium-106.Apple’s iPhone X has a screen that covers the entire face of the phone, save for a “notch” to make space for a camera and other various components. Juxtapapillary choroidal melanomas treated with notched ruthenium plaques have a high recurrence rate and frequently need salvage treatment with PBT for tumour control. ![]() The observed risk of recurrence over 5 years was 31% (95% CI: 14.1%, 47.8%), and the risk of enucleation over 5 years was 11.5% (95% CI: 0.9%, 21.8%). ![]() Complications included maculopathy (10%), retinal detachment (5%), neovascular glaucoma (2.5%), and diplopia (2.5%). Six of these were treated with salvage proton beam therapy (PBT), 2 with transpupillary thermotherapy followed by PBT, and 5 with enucleation. Over the maximum follow-up time, 13 tumours (32.5%) recurred. The median follow-up was 51 months (14-100 months). The mean presenting vision was 0.3 logMAR, and the mean final vision was 0.7 logMAR, with 62.5% retaining >1.0 logMAR and 50% retaining >0.3 logMAR at the final follow-up. AJCC tumour category distribution was 62.5% T1, 32.5% T2, and 5% T3 tumours. We reviewed 40 patients with a median tumour diameter of 8.4 mm (range 5-17 mm) and a median thickness of 2.5 mm (range 1.1-6 mm). The data were analysed with respect to various outcome measures including recurrence, complications, vision, and eye preservation. ![]() Juxtapapillary choroidal melanomas (tumours within 2 disc diameters from the optic disc) treated with notched ruthenium-106 plaques (Eckert & Ziegler, BEBIG, Berlin, Germany) at the Scottish Ocular Oncology Service between 20 were retrospectively reviewed. This study aimed to evaluate the outcomes of juxtapapillary choroidal melanomas treated with notched ruthenium-106 plaques. ![]()
0 Comments
Leave a Reply. |